Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
associated decrease » associated increase (Expand Search), associated disease (Expand Search), associated diseases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
associated decrease » associated increase (Expand Search), associated disease (Expand Search), associated diseases (Expand Search)
-
3401
-
3402
-
3403
-
3404
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
3405
-
3406
-
3407
-
3408
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
3409
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
3410
-
3411
-
3412
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
3413
-
3414
-
3415
-
3416
-
3417
-
3418
-
3419
-
3420
Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>.
Published 2025Subjects: